10x Genomics Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
10x Genomics (TXG) Tops Q3 EPS by 4c, Misses on Revenue; Offers FY24 Revenue Guidance
October 29, 2024 4:12 PM EDT10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $151.7 million versus the consensus estimate of $158.84 million.
GUIDANCE:
10x Genomics sees FY2024 revenue of $640-660 million, versus the consensus... More



